PharmiWeb Today Story
Noninvasive urine-based biomarker testing can support routine testing for graft dysfunction
WEST HILLS, Calif.--(BUSINESS WIRE)-- For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications. Now, a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a kidney transplant.
Thermo Fisher Scientific One Lambda Laboratories, a CLIA facility in Fishers, Ind., has introduced a new CXCL10 testing service, which allows for non-invasive urine sample collection and testing, with results available in as little as 24 hours, providing valuable information faster than currently used tests. Multiple studies have shown that elevated urinary CXCL10 levels are associated with inflammation and early kidney transplant rejection, as outlined in a recent article in Current Opinion in Organ Transplantation.
“Current methods of post-transplant monitoring can represent a significant financial and physical burden for many transplant patients. In keeping with our commitment to health equity, we believe this lower-cost, non-invasive testing option can expand access to care and improve patient adherence, since the sample can be collected at any local clinic,” says Chris McCloskey, director, Transplant Services, Thermo Fisher Scientific.
Thermo Fisher’s CXCL10 testing service may supplement current standards of care that may lack specificity or sensitivity, whi…
Read More...Articles
Top 6 Pharmaceutical Companies in the UK 2024
30-Apr-2024
What Does a Clinical SAS Programmer Do?
16-Apr-2024
The Evolution of Clinical Data Management
10-Apr-2024
9 Clinical Data Management Career Paths
08-Apr-2024
Featured Events
-
Pharmaceutical Manufacturing & Packaging Congress…
28-Jun-2021 - 29-Jun-2021 -
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021 -
Reuters Events: Cell & Gene Therapy USA 2021
28-Sep-2021 - 29-Sep-2021 -
Pharma USA 2022
16-Mar-2022 - 17-Mar-2022 -
AI in Healthcare Summit Boston 2022
13-Oct-2022 - 14-Oct-2022 -
Genomics and Precision Medicine Expo
23-May-2023 - 24-May-2023
News
-
Catheter Precision, Inc. (NYSE American: VTAK) Rep…
06-May-2024 -
NHI Issues Investor Update
06-May-2024 -
NHI Announces Second Quarter 2024 Dividend
06-May-2024 -
NHI Announces First Quarter 2024 Results
06-May-2024 -
Bioz and WiCell Launch New Collaboration to Bring…
06-May-2024 -
Gene Therapy Market Set for Exponential Growth, Pr…
06-May-2024